Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131366 | 0.98 | MAPT (0.43) | MAPTHRH3ADRA1AL3MBTL3L3MBTL1 | |
| SCHEMBL4136714 | 0.91 | L3MBTL3 (0.51) | HRH3ADRA1AL3MBTL3L3MBTL1 | |
| SCHEMBL4289427 | 0.90 | L3MBTL3 (0.50) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL4130945 | 0.88 | HRH3 (0.43) | MAPTHRH3L3MBTL3L3MBTL1DGAT1 | |
| SCHEMBL4938014 | 0.87 | HRH3 (0.42) | MAPTHRH3L3MBTL3L3MBTL1DGAT1 | |
| SCHEMBL4147059 | 0.87 | HRH3 (0.45) | HRH3DGAT1 | |
| SCHEMBL4427957 | 0.86 | MAPT (0.42) | MAPTHRH3ADRA1ADGAT1 | |
| SCHEMBL4428129 | 0.86 | SMN1; SMN2 (0.46) | MAPTHRH3ADRA1AL3MBTL3L3MBTL1 | |
| SCHEMBL4932074 | 0.86 | L3MBTL3 (0.39) | HRH3ADRA1AL3MBTL3L3MBTL1CHRM4 | |
| SCHEMBL4280892 | 0.86 | L3MBTL3 (0.39) | HRH3ADRA1AL3MBTL3L3MBTL1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | MAPT 1220/4885HRH3 1/4885ADRA1A 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.